Julian F.R. Paton

Jul 11, 2024 | erj.ersjournals.com | Michael Plunkett |Tanya J McWilliams |Julian F.R. Paton |James Fisher

AcknowledgementsThe authors wish to thank all the volunteers for their valuable participation in this study, and Marie Mata for assistance with patient recruitment and study procedures. FootnotesThis clinical trial was prospectively registered as ACTRN12622000505707. Ethics statement: This study was approved by the Health and Disability Ethics Committee (HDEC 2022 FULL 12454).

Jan 4, 2024 | erj.ersjournals.com | Michael Plunkett |Tanya J McWilliams |Julian F.R. Paton |James Fisher

To the Editor:Impairment of exercise capacity, predominantly limited symptomatically by dyspnoea [1], affects most patients with pulmonary arterial hypertension (PAH) despite current therapies [2], with significant implication for patients, adversely impairing health-related quality of life [3] and clinical prognosis [4]. However, the underpinning physiological mechanisms behind dyspnoea and exercise limitation remain incompletely understood.